Literature DB >> 1301945

Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.

E Ikonen1, L Peltonen.   

Abstract

This article provides a review of the mutations reported so far in the lysosomal storage disease aspartylglucosaminuria (AGU). The clinical symptoms, biochemical findings, and diagnostic possibilities of the disease are introduced. The prevalence and biological consequences of the found mutations are then described, as well as the availability of a new rapid DNA test suitable for carrier screening. This test will be especially applicable in the genetically isolated Finnish population, where the carrier frequency of AGU was found to be as high as 1:36. Finally, future prospects dealing with the foreseeable therapeutic interventions of the disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301945     DOI: 10.1002/humu.1380010503

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  4 in total

1.  Sleep disturbances in aspartylglucosaminuria (AGU): a questionnaire study.

Authors:  Niki Lindblom; Satu Kivinen; Hannu Heiskala; Maija-Liisa Laakso; Markus Kaski
Journal:  J Inherit Metab Dis       Date:  2006-08-30       Impact factor: 4.982

2.  Linkage disequilibrium mapping in isolated populations: the example of Finland revisited.

Authors:  A de la Chapelle; F A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

3.  Aspartylglucosaminuria among Palestinian Arabs.

Authors:  J Zlotogora; Z Ben-Neriah; B Y Abu-Libdeh; V Sury; M Zeigler
Journal:  J Inherit Metab Dis       Date:  1997-11       Impact factor: 4.982

4.  Functional Analysis of the Ser149/Thr149 Variants of Human Aspartylglucosaminidase and Optimization of the Coding Sequence for Protein Production.

Authors:  Antje Banning; Jan F König; Steven J Gray; Ritva Tikkanen
Journal:  Int J Mol Sci       Date:  2017-03-26       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.